A Novel Approach to Identify Smooth Muscle Relaxants

Information

  • Research Project
  • 6403819
  • ApplicationId
    6403819
  • Core Project Number
    R43HL068349
  • Full Project Number
    1R43HL068349-01
  • Serial Number
    68349
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/28/2001 - 22 years ago
  • Project End Date
    3/27/2002 - 22 years ago
  • Program Officer Name
    ROTHGEB, ANN E.
  • Budget Start Date
    9/28/2001 - 22 years ago
  • Budget End Date
    3/27/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/28/2001 - 22 years ago
Organizations

A Novel Approach to Identify Smooth Muscle Relaxants

DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) and especially asthma affect millions of Americans. As of 1995, an estimated 14.9 million persons suffer chronic symptoms. Despite several different therapeutic approaches, disease severity also is on the rise as reflected by increasing mortality rates. The treatment of COPD and asthma relies on long-term reduction of the chronic inflammatory response and acute symptomatic control by the use of bronchodilators. In the latter class, inhaled Beta adrenergic agents are most commonly used but suffer from reduced efficacy with prolonged use secondary to receptor desensitization. We propose to begin development of a new class of bronchodilators that act directly on the target responsible for force generation, the motor protein smooth muscle myosin. We plan to introduce this target into Cytokinetic's robust high throughput screening technology to discover compounds that will act via this unique mechanism. Using biochemical and physiological means, these compounds will be screened for secondary undesirable properties and then tested in semi-intact systems. We expect to identify chemical compounds that have the potential to demonstrate proof of principle in relevant models of bronchoconstriction. These compounds may then eventually lead to a novel pharmacologic class of smooth muscle relaxants with applicability in other therapeutic areas. PROPOSED COMMERCIAL APPLICATIONS: Given the number of individuals that use bronchodilators in various lung diseases, the potential market is enormous. The estimated 2002 market size for the most widely used inhaled beta-adrenergic agents (albuterol and salmeterol) is $1.3 billion dollars (Med Ad News, 2000, Vol. 19, p. 59). Agents that directly target the contractile machinery could be used either as adjunctive therapy or potentially as a primary agent. In addition, a potent smooth muscle relaxant may have applications in the other large therapeutic areas such as hypertension, pre-term labor, and bladder spasmaticity leading to incontinence.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99900
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    838
  • Ed Inst. Type
  • Funding ICs
    NHLBI:99900\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CYTOKINETICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOUTH SAN FRANCISCO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94080
  • Organization District
    UNITED STATES